Perrigo Company plc is separating its Prescription Pharmaceuticals (Rx) business following the company’s strategic portfolio review. According to the company, a separation of the Rx business will better enable this asset to capitalize on its platform of differentiated generic pharmaceutical products and allows Perrigo to focus on expanding its consumer business. The company is considering all options, including a possible separation to shareholders, a sale or merger.    The Rx business ...